Swiss startup hephaistos.bio has secured €161,000 in seed funding to further develop its AI-powered platform for custom enzyme design in chemical and pharmaceutical manufacturing. The funding, provided by Venture Kick, will support efforts to enhance sustainability and efficiency in traditionally resource-intensive industries.
The MIT Corporation has elected ten new term members and two life members to its board of trustees, including leaders from technology, healthcare, and AI sectors. Notable appointees include Elizabeth Choe, director of AI strategy for translational medicine at AstraZeneca, underscoring the board’s expertise in artificial intelligence applications within healthcare.
Researchers have discovered a common weakness found across hundreds of cancer mutations, paving the way for potential new treatments. The study highlights how artificial intelligence tools support understanding complex genetic patterns in cancer. The breakthrough may help in the development of targeted therapies.
Manchester-based Imperagen has secured £5 million in seed funding to expand its AI-driven enzyme engineering platform. The company aims to accelerate R&D and scale operations, targeting applications across pharmaceuticals, life sciences, and sustainable chemicals.
Imperagen has secured £5 million to advance the use of quantum physics and artificial intelligence in enzyme engineering. The funding aims to accelerate the development of custom enzymes with potential applications in biotechnology and life sciences.
The Marble Center for Cancer Nanomedicine at MIT marked its ten-year milestone, highlighting advances in cancer detection and treatment through nanotechnology and artificial intelligence. The center has catalyzed new collaborations, launched multiple startups, and emphasized the translation of research into clinical and commercial applications. Recent initiatives include AI-based approaches for faster development of RNA therapies, accelerating progress toward more precise and effective cancer care.
Researchers have built an artificial intelligence device that incorporates living brain cells, marking a significant step in merging biological materials with AI technology. This innovation demonstrates the potential for hybrid AI systems that combine organic and computational elements.
Isomorphic Labs has announced a $2.1 billion Series B funding round to accelerate its AI-driven drug discovery initiatives. The financing, led by Thrive Capital and supported by Alphabet and other major investors, will be used to enhance the company’s drug design platform and expand its research into treatments for cancer and immune disorders.
MIT Associate Professor Joey Davis is advancing the understanding of ribosome assembly through the use of neural networks and machine learning. His lab’s work with cryo-electron microscopy and AI-based models promises to enhance protein structure prediction and could impact biotechnology and healthcare research.
A team from Columbia and Harvard has experimentally reduced the genetic code from 20 to 19 amino acids by engineering a ribosome that functions without isoleucine. This research could shed light on the evolution of the genetic code and the fundamentals of synthetic biology.
Stay informed with curated insights delivered weekly to your inbox.